Witryna1 lip 2024 · Abstract. Background Platinum chemotherapy (carboplatin or cisplatin) + etoposide is the current 1L standard of care treatment (tx) for ES-SCLC. Despite high response rates on this regimen, patient (pt) outcomes remain poor. IMpower133 is a Ph1/3, double-blind, randomized, placebo (PBO)-controlled trial that is evaluating the … Witryna另外,两项III期研究显示PD-L1抑制剂联合化疗一线治疗广泛期SCLC(extensive-stage small cell lung cancer, ES-SCLC)的疗效优于单纯化疗:在IMpower133研究中,阿替利珠单抗联合化疗的总生存期(overall survival, OS)为12.3个月,死亡风险较单纯化疗减少30%[12];在CASPIAN研究中 ...
Full article: Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a ...
Witryna7 paź 2024 · IMpower133研究入组的是一般状态较好(PS 0-1分)的患者,对患者的组织标本没有要求,对照组与预期结果相符,毒性可以预期和管理。 亚组分析显 … WitrynaIMpower133, a global Ph1/3, double-blind, randomized, placebo (PBO)-controlled trial evaluated efficacy and safety of adding atezolizumab (atezo; anti–PD-L1) or PBO to 1L tx (NCT02763579). Methods: Patient (pts) without prior tx for ES-SCLC were enrolled. PD-L1 testing was not required. imgview.com earn
IMpower133: Phase I/III trial of first-line atezolizumab with ...
Witryna13 wrz 2024 · Schematy leczenia chemio- i immunoterapią znalazły swoje zastosowanie również w leczeniu chorych z drobnokomórkowym rakiem płuca. W badaniach … Witryna11 kwi 2024 · Introduction. Approximately 15% of lung cancer cases are small-cell lung cancer (SCLC), which has a poor prognosis ().Platinum-based chemotherapy has been the standard first-line treatment for both limited-stage (LS) and extensive-stage (ES) disease since the 1980s, with an objective response rate (ORR) of about 65% and a … Witryna13 sty 2024 · IMpower133 was a global, phase I/III double-blind, randomized, placebo-controlled trial, whose design and primary results have been previously reported … imgview charity